11. Diagonal Bio AB: "Our latest external study delivered extremly good results in line with our expectations" - Jack Egelund Madsen, CEO

FinVoices

Impala Nordic에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Impala Nordic 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

1+ y ago 24:04

MP3•에피소드 홈

Jack Egelund Madsen, CEO at Diagonal Bio AB (publ), joins FinVoices to speak about the company and share the updates regarding Diagonal Bios latest and upcoming milestones.

The latest results from the external study have proven that Diagonal Bios platform technology are delivering the quality, speed and sensitivity in line with our expectations, and more. Further, Jack explains the main focus for this year is to commercialize LAMPlify.

// Diagonal Bio AB (publ) is a biotech company based in Lund. The company is developing two platforms developed on their own patented technology, PANVIRAL and LAMPlify, to detect genetic markers in genetic material (DNA or RNA based) regardless if this is originating from humans, animals, plants, viruses, bacteria and fungi. //

FinVoices is operated by Impala Nordic.

Disclaimer** Nothing said in the podcast is a buy or sell recommendation. This episode has been done on behalf of the company.

Hosted on Acast. See acast.com/privacy for more information.

35 에피소드

#Handel #Högre Utbildning #Entreprenör #Affärer #Utbildning #Impala Nordic #Aktier #Ekonomi #Sparande #Investeringar #Fonder #Finans #Finansiell Ekonomi